Get the Stockscreener App
428.34
0.76%
3.25
After Hours:
431.00
2.66
+0.62%
Vertex Pharmaceuticals Inc stock is traded at $428.34, with a volume of 1.57M.
It is up +0.76% in the last 24 hours and up +1.04% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$425.09
Open:
$420.63
24h Volume:
1.57M
Relative Volume:
1.22
Market Cap:
$108.72B
Revenue:
$12.34B
Net Income/Loss:
$4.34B
P/E Ratio:
25.39
EPS:
16.8685
Net Cash Flow:
$3.71B
1W Performance:
-2.03%
1M Performance:
+1.04%
6M Performance:
-7.51%
1Y Performance:
-4.06%
1-Day Range:
$420.01
$429.01
1-Week Range:
$420.01
$450.00
52-Week Range:
$362.50
$507.92
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
428.34 | 107.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
618.95 | 63.21B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
813.14 | 49.89B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.58 | 38.20B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.99 | 32.17B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Upgrade | Maxim Group | Hold → Buy |
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex (VRTX) legal chief sells 828 shares in pre-set 10b5-1 trade - Stock Titan
Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 - Business Wire
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential - The Motley Fool
Vertex (VRTX) Up 0.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance Singapore
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Madrigal Pharmaceuticals Stock Could Become The Next Vertex (NASDAQ:MDGL) - Seeking Alpha
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals Inc stock (US92532F1003): shares slip after insider sales and FDA update on p - AD HOC NEWS
Is Vertex Pharmaceuticals (VRTX) Offering An Opportunity After Recent Share Price Consolidation? - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Down by 3.03% on Jun 2: Facts Behind the Movement - TradingKey
Vertex Pharmaceuticals Insider Sold Shares Worth $888,300, According to a Recent SEC Filing - marketscreener.com
Vertex (VRTX) CMO executes 1,974-share planned sale, retains holdings - Stock Titan
Should FDA’s IgA Nephropathy BLA Acceptance for Povetacicept Reshape Vertex Pharmaceuticals’ (VRTX) Investment Narrative? - Yahoo Finance
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy - Yahoo Finance Singapore
Vertex Pharmaceuticals Inc stock (US92532F1003): insider sales and Q1 2026 figures in focus - AD HOC NEWS
Acute Pain Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Vertex Pharma, Heron Therapeutics, Neumentum, Cali Biosciences - Barchart.com
Vertex Pharma stock (US92532F1003): FDA accepts povetacicept filing as shares trade steady on Nasdaq - AD HOC NEWS
Vertex Pharmaceuticals stock: Is VRTX underperforming the healthcare sector? - MSN
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Vertex Pharmaceuticals (NASDAQ: VRTX) insider Joy Liu reports share sales - Stock Titan
Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector? - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Receives FDA BLA Acceptance for Po - GuruFocus
Vertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious? - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance Singapore
FDA accepts Vertex filing for IgAN drug povetacicept By Investing.com - Investing.com Canada
Vertex announces US FDA acceptance of biologics license application for accelerated approval of povetacicept in IgA nephropathy - marketscreener.com
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy - Business Wire
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX): Affordable Growth with Strong Fundamentals - ChartMill
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
MFS Core Equity Portfolio's Vertex Pharmaceuticals Inc(VRTX) Holding History - GuruFocus
Vertex Pharma stock (US92532F1003): Insider sales and Norges Bank stake highlight ownership dynamics - AD HOC NEWS
Committee Stocks On The Move: Uber And Vertex Pharma Dybala (RYo07l9B0s) - Mshale
Is Vertex Pharmaceuticals Successfully Diversifying Beyond Cystic Fibrosis - Kavout
Vertex Pharmaceuticals (VRTX) affiliate reports multiple share sales, proceeds listed - Stock Titan
Vertex Pharma stock (US92532F1003): Valuation stays in focus after a fresh move - AD HOC NEWS
VRTX: Renal franchise set to rival CF as new therapies and launches drive next phase of growth - TradingView
VRTX News | VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) - ChartMill
Vertex (VRTX) Announces Health Canada Acceptance of NDS for Suzetrigine - Insider Monkey
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals Inc stock (US92532F1003): Texas pension fund disclosure spotlights biotech he - AD HOC NEWS
These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth - Yahoo Finance
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - PR Newswire
Vertex’s Journavx made history, but left a void in the pain space - Pharma Voice
Viridian, awaiting FDA decision, taps WuXi Bio in supply deal - Fierce Pharma
Truist Financial Upgrades Vertex Pharmaceuticals(VRTX.US) to Buy Rating, Announces Target Price $542 - Moomoo
Vertex Pharmaceuticals Incorporated Shs Cert Deposito Arg Repr 0.00990099 Shs - TradingView
Ending the Pharma Relay Race with a Non-Opioid Breakthrough - Pharmaceutical Executive
Layoff Tracker: J&J trims New Jersey headcount by 56 - BioSpace
Truist assumes Vertex stock coverage with buy rating on kidney drugs - Investing.com
Vertex Pharma stock (US92532F1003): cystic fibrosis franchise underpins valuation as investors weigh - AD HOC NEWS
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):